{"id":"NCT01327846","sponsor":"Novartis Pharmaceuticals","briefTitle":"Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-11","primaryCompletion":"2017-03-28","completion":"2019-04-14","firstPosted":"2011-04-04","resultsPosted":"2020-01-22","lastUpdate":"2020-01-22"},"enrollment":10066,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atherosclerosis"],"interventions":[{"type":"DRUG","name":"Canakinumab","otherNames":["ACZ885"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Standard of care","otherNames":[]}],"arms":[{"label":"Canakinumab Dose 50 mg","type":"EXPERIMENTAL"},{"label":"Canakinumab Dose 150 mg","type":"EXPERIMENTAL"},{"label":"Canakinumab Dose 300 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events.\n\nThe purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who participated in the pivotal phase.\n\nSub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS).\n\nSub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion and insulin sensitivity.","primaryOutcome":{"measure":"Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components","timeFrame":"From randomization, to end of treatment plus 30 days, up to approximately 6 years","effectByArm":[{"arm":"Group I","deltaMin":322,"sd":null},{"arm":"Group II","deltaMin":320,"sd":null},{"arm":"Group III","deltaMin":313,"sd":null},{"arm":"Group IV","deltaMin":535,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0648"},{"comp":"OG001 vs OG003","p":"0.0241"},{"comp":"OG002 vs OG003","p":"0.1895"},{"comp":"OG000 vs OG003","p":"0.572"},{"comp":"OG001 vs OG003","p":"0.296"},{"comp":"OG002 vs OG003","p":"0.369"},{"comp":"OG000 vs OG003","p":"0.067"},{"comp":"OG001 vs OG003","p":"0.006"},{"comp":"OG002 vs OG003","p":"0.542"},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG003","p":"0.190"},{"comp":"OG001 vs OG003","p":"0.912"},{"comp":"OG002 vs OG003","p":"0.871"},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":1131,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Colombia","Croatia","Czechia","Estonia","Germany","Greece","Guatemala","Hungary","Iceland","India","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Norway","Peru","Poland","Puerto Rico","Romania","Russia","Serbia","Slovakia","Slovenia","South Africa","South Korea","Sweden","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["37934948","35943897","35385050","33004131","32744862","32203978","31884854","31504417","30586730","30242335","30165610","29793629","29544870","29146124","28855077","28845751","26546248","21982649"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":759,"n":2263},"commonTop":["Viral upper respiratory tract infection","Hypertension","Back pain","Arthralgia","Upper respiratory tract infection"]}}